Path Fertility secures $2 million NIH grant to develop and validate a semen-based epigenetic assay for NOA and cancer risk.
Agendia presented data on an AI pathology model that predicts breast cancer recurrence risk from routine biopsy slides.
Tempus xR RNA sequencing assay receives EU IVDR Class C certification, supporting continued clinical and biopharma access in ...
Abbott launches its Oncodetect MRD test, using WGS to track up to 5,000 variants and improve cancer recurrence detection sensitivity.
FDA grants bioMérieux dual clearance and CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis Panel, a rapid 20-minute ...
Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.
Quest Diagnostics and Waters will expand at-home HPV screening in 2027, offering extended genotyping via the Onclarity ...
Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its breast cancer genomic testing portfolio, the ...
Illumina has introduced three early-access software capabilities on its BioInsight Platform designed to automate informatics ...
Gene by Gene will provide whole-genome sequencing for Children’s Mercy’s program, targeting nearly 100,000 pediatric genomes.
Hologic and Inpeco have partnered to connect Panther Systems with FlexLab X automation in Europe, aiming to improve ...
A study finds permissive lab screening thresholds double primary aldosteronism detection rates versus Endocrine Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results